CEFEPIME

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C19H24N6O5S2
Molecular Weight	480.561
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	1
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@]12SCC(C[N+]3(C)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C4=CSC(N)=N4)C([O-])=O

InChI

InChIKey=HVFLCNVBZFFHBT-ZKDACBOMSA-N

InChI=1S/C19H24N6O5S2/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29)/b23-12-/t13-,17-/m1/s1

HIDE SMILES / InChI

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf
Curator's Comment: description was created based on several sources, including: http://www.rxlist.com/maxipime-drug.htm https://www.drugs.com/cdi/cefepime.html

Cefepime is a fourth-generation cephalosporin antibiotic, which was developed in 1994. Cefepime has a broad spectrum in vitro activity that encompasses a wide range of Gram-positive and Gram-negative bacteria. Within bacterial cells, the molecular targets of cefepime are the penicillin binding proteins (PBP). It is FDA approved for the treatment of pneumonia, febrile neutropenia, uncomplicated UTI, uncomplicated skin infection and complicated intraabdominal infections. Common adverse reactions include rash, hypophosphatemia, diarrhea. Cefepime is metabolized to N-methylpyrrolidine (NMP) which is rapidly converted to the N-oxide (NMP-N-oxide). Urinary recovery of unchanged cefepime accounts for approximately 85% of the administered dose. Less than 1% of the administered dose is recovered from urine as NMP, 6.8% as NMP-N-oxide, and 2.5% as an epimer of cefepime. Because renal excretion is a significant pathway of elimination, patients with renal dysfunction and patients undergoing hemodialysis require dosage adjustment.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Bacterial penicillin-binding protein 233 Target ID: CHEMBL2354204 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8150771	Inhibitor 8297

Conditions

Condition	Modality	Highest Phase	Product
Pneumonia 90 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf	Curative	Approved 8429	MAXIPIME Approved Use Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1996
Urinary tract infections 205 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf	Curative	Approved 8429	MAXIPIME Approved Use Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1996
Febrile neutropenia 5 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf	Curative	Approved 8429	MAXIPIME Approved Use Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1996
Uncomplicated skin and skin-structure infections 21 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf	Curative	Approved 8429	MAXIPIME Approved Use Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1996
Complicated intra-abdominal infections 20 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/050679s040lbl.pdf	Curative	Approved 8429	MAXIPIME Approved Use Cefepime for injection, USP is indicated in the treatment of the following infections caused by susceptible strains of the designated microorganisms (see also PRECAUTIONS: Pediatric Use and DOSAGE AND ADMINISTRATION ): Pneumonia (moderate to severe) caused by Streptococcus pneumoniae, including cases associated with concurrent bacteremia, Pseudomonas aeruginosa, Klebsiella pneumoniae , or Enterobacter species. Empiric Therapy for Febrile Neutropenic Patients. Cefepime as monotherapy is indicated for empiric treatment of febrile neutropenic patients. In patients at high risk for severe infection (including patients with a history of recent bone marrow transplantation, with hypotension at presentation, with an underlying hematologic malignancy, or with severe or prolonged neutropenia), antimicrobial monotherapy may not be appropriate. Insufficient data exist to support the efficacy of cefepime monotherapy in such patients. (See CLINICAL STUDIES .) Uncomplicated and Complicated Urinary Tract Infections (including pyelonephritis) caused by Escherichia coli or Klebsiella pneumoniae, when the infection is severe, or caused by Escherichia coli, Klebsiella pneumoniae , or Proteus mirabilis, when the infection is mild to moderate, including cases associated with concurrent bacteremia with these microorganisms. Uncomplicated Skin and Skin Structure Infections caused by Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Complicated Intra-abdominal Infections (used in combination with metronidazole) caused by Escherichia coli, viridans group streptococci, Pseudomonas aeruginosa, Klebsiella pneumoniae , Enterobacter species, or Bacteroides fragilis. (See CLINICAL STUDIES .) To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefepime for injection, USP and other antibacterial drugs, cefepime for injection, USP should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Launch Date 1996

C_max

Value	Dose	Analyte	Population
29.6 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
81.7 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
57.5 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
163.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
13.9 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	500 mg single, intramuscular dose: 500 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
39.1 μg/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
137 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	1 g single, intramuscular dose: 1 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
148.5 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	1 g single, intravenous dose: 1 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
262 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	2 g single, intramuscular dose: 2 g route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
284.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	2 g single, intravenous dose: 2 g route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
60 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	500 mg single, intramuscular dose: 500 mg route of administration: Intramuscular experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN
70.8 μg × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered:	CEFEPIME HYDROCHLORIDE plasma	Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
2 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	unknown, unknown		CEFEPIME HYDROCHLORIDE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
80% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/050679s042lbl.pdf	unknown, unknown		CEFEPIME HYDROCHLORIDE serum	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
2 g 3 times / day multiple, intravenous Highest studied dose\|Recommended Dose: 2 g, 3 times / day Route: intravenous Route: multiple Dose: 2 g, 3 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/31549737	unhealthy, 53.2 years n = 10 Health Status: unhealthy Condition: Renal Replacement Therapy Age Group: 53.2 years Sex: M+F Population Size: 10 Sources: https://pubmed.ncbi.nlm.nih.gov/31549737	Sources: https://pubmed.ncbi.nlm.nih.gov/31549737
1 g 2 times / day multiple, intravenous\|intramuscular Dose: 1 g, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 1 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (1.1%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
2 g 2 times / day multiple, intravenous\|intramuscular Dose: 2 g, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 2 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
500 mg 2 times / day multiple, intravenous\|intramuscular Dose: 500 mg, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 500 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	Disc. AE: Rash... AEs leading to discontinuation/dose reduction: Rash (0.8%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf

AEs

AE	Significance	Dose	Population
Rash	1.1% Disc. AE	1 g 2 times / day multiple, intravenous\|intramuscular Dose: 1 g, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 1 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
Rash	2% Disc. AE	2 g 2 times / day multiple, intravenous\|intramuscular Dose: 2 g, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 2 g, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf
Rash	0.8% Disc. AE	500 mg 2 times / day multiple, intravenous\|intramuscular Dose: 500 mg, 2 times / day Route: intravenous\|intramuscular Route: multiple Dose: 500 mg, 2 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/065369_original_approval_pkg.pdf

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:478164	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:478164
ChemicalBook	CB1737417	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1737417
MolPort	MolPort-006-167-794	https://www.molport.com/shop/molecule-link/MolPort-006-167-794

PubMed

Title	Date	PubMed
Efficacy of cefepime in a Staphylococcus aureus endocarditis rat model.	1993 Nov	8150772
Nonconvulsive status epilepticus associated with cephalosporins in patients with renal failure.	2001 Aug	11498064
Retrospective analysis of drug-induced urticaria and angioedema: a survey of 2287 patients.	2001 Nov	11792017
Metronidazole-induced encephalopathy in a uremic patient: a case report.	2001 Sep	11528241
Reversible metronidazole-induced lesions of the cerebellar dentate nuclei.	2002 Jan 3	11778010
Cefepime: a review of its use in the management of hospitalized patients with pneumonia.	2003	14720024
Retrospective review of neurotoxicity induced by cefepime and ceftazidime.	2003 Mar	12627936
Neurotoxicity induced by Cefepime in a very old hemodialysis patient.	2003 May	12779103
Effects of some antibiotics on human erythrocyte 6-phosphogluconate dehydrogenase: an in vitro and in vivo study.	2004 Aug	15558954
Cefepime- and cefixime-induced encephalopathy in a patient with normal renal function.	2005 Dec 13	16344542
Invasive fungal infection of the maxilla following dental extractions in a patient with chronic obstructive pulmonary disease.	2006 Mar	16545177
Probable trimethoprim/sulfamethoxazole-induced higher-level gait disorder and nocturnal delirium in an elderly man.	2009 Jan	19109207
Cefepime-related encephalopathy in peritoneal dialysis patients.	2011 Feb	21354086
Investigation of the effects of some drugs and phenolic compounds on human dihydrofolate reductase activity.	2015 Mar	25418905
Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.	2015 May 18	25811541

Patents

Sample Use Guides

In Vivo Use Guide

Moderate to Severe Pneumonia: 1 to 2 g IV, every 8 to 12 hours; 10 days. Empiric therapy for febrile neutropenic patients: 2 g IV, every 8 hours; 7 days. Mild to Moderate Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis: 0.5 to 1 g IV/IM, every 12 hours; 7 to 10 days. Severe Uncomplicated or Complicated Urinary Tract Infections, including pyelonephritis: 2 g IV, every 12 hours; 10 days. Moderate to Severe Uncomplicated Skin and Skin Structure Infections: 2 g IV, every 12 hours; 10 days. Complicated Intra-abdominal Infections (used in combination with metronidazole): 2 g IV, every 8-12 hours; 7 to 10 days.

Route of Administration: Other

In Vitro Use Guide

Cefepime showed excellent activity against E. coli and K. pneumoniae, inhibiting 90% of these isolates at 0.12 mg/l. 84 isolates of methicillin-susceptible S. aureus were inhibited by 8 mg/l of cefepime.

Name

Type

Language

CEFEPIME

Official Name

English

1-(((6R,7R)-7-(2-(2-AMINO-4-THIAZOLYL)GLYOXYLAMIDO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-METHYLPYRROLIDINIUM HYDROXIDE, INNER SALT, 7(SUP 2)-(Z)-(O-METHYLOXIME)

Common Name

English

VNRX-5022

Code

English

Cefepime [WHO-DD]

Common Name

English

CEFEPIME [MI]

Common Name

English

cefepime [INN]

Common Name

English

CEFEPIME [USAN]

Common Name

English

PYRROLIDINIUM, 1-((7-(((2-AMINO-4-THIAZOLYL)(METHOXYIMINO)ACETYL)AMINO)-2-CARBOXY-8-OXO-5-THIA-1-AZABICYCLO(4.2.0)OCT-2-EN-3-YL)METHYL)-1-METHYL-, HYDROXIDE, INNER SALT, (6R-(6.ALPHA.,7.BETA.(Z)))-

Common Name

English

CEFEPIME [VANDF]

Common Name

English

J01DE01

Code

English

BMY-28142

Code

English

Classification Tree Code System Code

NDF-RT

N0000011161